Skip to content
MarketScale
‹ Back to IndustriesSciences

“Stronger Together”: 2022 Abu Dhabi Space Debate Shows Cooperation is Both Key and a Challenge

The 2022 Abu Dhabi Space Debate highlighted how international cooperation is simultaneously essential and complex for the next generation of space projects. Both public and private sector stakeholders are navigating how to collaborate across national boundaries as commercialization and scientific exploration opportunities expand. The debate underscored that partnership frameworks will be critical to shaping the future of the space industry.

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Ryan Duffy · 2022 Abu Dhabi Space DebatePayloadSpace CommercializationSpace Exploration
Share

Key takeaways

01

International cooperation is a defining challenge and necessity for the future of space exploration and commercialization.

02

Public and private sector roles in space are evolving rapidly, requiring new frameworks for cross-border collaboration.

03

The 2022 Abu Dhabi Space Debate served as a key forum for governments and industry leaders to address these cooperation challenges.

The future of public and private space use is being defined in real time, as the possibilities for commercialization, further scientific discoveries, and key government projects expand their horizons. A critical part of the next phase of space projects will be deciding how various countries’ projects will seek a helping hand from across national lines, whether in a formal partnership or a crowdsourcing of expertise. Luckily, the 2022 Abu Dhabi Space Debate is one of the hubs leading this important discussion for the role of cooperation in

The 2022 Abu Dhabi Space Debate, hosted by the UAE Space Agency, is an international two-day conference acting as a global forum for space industry researchers, policy makers, whole nations, and business leaders to “address the issues facing growth and innovation in space.” The Presidents of India and the UAE, along with top leadership at UAE, Saudi, French, Norwegian, Polish, and EU space agencies, gathered for keynote speeches, moderated debates, and collaborative discussions on topics like foreign policy strategy, space sustainability, national security, and the rise of the private sector in space exploration and development.

What were the main takeaways from the show? And what stands in the way of a unified approach to exploring the stars and creating commercial value from everything from in-orbit satellites to space tourism? Ryan Duffy, managing editor at modern space media brand Payload, and a speaker at the 2022 Abu Dhabi Space Debate, weighs the push and pull of mutual benefit for future space projects.

Ryan’s Thoughts

“Big takeaway is there’s a lot of reasons to be optimistic. You know, stronger together. Cooperation is better than competition in space. There are many situations where one plus one can equal three and it’s advantageous to work together. That said, many of the leaders that I spoke to, acknowledge that there are factors like national security, prestige, self-interested national policy that drive space programs.

Another theme is that space is being democratized. You know, more and more countries are creating their own space agencies and pushing forward into the stars, say for launch, maybe, because only a fraction of the countries that space agencies have their own sovereign launch capabilities.

Another theme don’t look to the stars with entirely rose-tinted glasses. You know, there’s overcrowding of key orbit, risk of space debris, militarization of space assets, cybersecurity vulnerabilities of on orbit hardware. But by and large, it’s a fast-moving space pun intended. And I saw a lot of positive signs and reasons to be optimistic. In fact, just when I was on the plane home from Abu Dhabi, 155 nations voted yes on a UN resolution calling for states not to commit destructive anti-satellite missile tests.”

About the author

RD
Ryan DuffyManaging Editor

Ryan leads editorial operations at Payload, a new digital media outfit covering the business of policy of space. Payload's flagship product, a daily newsletter, features a combination of original reporting, news curation, and industry analysis.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

RD
Ryan Duffy

Managing Editor

Ryan leads editorial operations at Payload, a new digital media outfit covering the business of policy of space. Payload's flagship product, a daily newsletter, features a combination of original reporting, news curation, and industry analysis.